PAR2 Inhibitor 1-PPA for Dual Transcription and Receptor Blocking

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

There is a lack of effective PAR2 inhibitors for treating a wide range of pathological conditions associated with PAR2 overexpression or activation, despite its therapeutic potential being recognized.

Innovation Solution

1-piperidine propionic acid (1-PPA) is identified as an inhibitor of PAR2, functioning at both the transcriptional and functional levels by inhibiting PAR2 RNA synthesis and interacting with the receptor's binding site, thereby reducing inflammatory cytokine synthesis and platelet aggregation.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If PAR2 inhibitors are developed for therapeutic use, then treatment effectiveness for PAR2-related pathological conditions is improved, but currently no clinically authorized PAR2 inhibitor exists despite extensive research

Engineering Contradiction:

Improvetherapeutic effectivenessVSAvoidclinical availability

Core Design Contradiction:

ReliabilityVSEase of manufacture

Solution Approach 1:

The patent employs 1-piperidine propionic acid (1-PPA), a simple, small-molecule compound that is chemically stable, easy to synthesize, and can be produced at low cost. This small molecule serves as an effective PAR2 inhibitor without requiring complex biological structures, enabling straightforward manufacturing and clinical translation.

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

2Manufacturing precision

If 1-PPA is used to inhibit PAR2 transcription and function, then PAR2 expression and activity are reduced, but the mechanism of action at both transcriptional and functional levels must be validated

Engineering Contradiction:

Improveinhibition efficacyVSAvoidmechanism validation

Core Design Contradiction:

Manufacturing precisionVSDifficulty of detecting and measuring

Solution Approach 1:

The patent divides the validation of 1-PPA's mechanism into two distinct segments: (1) transcriptional level validation through measurement of PAR2 mRNA expression, and (2) functional level validation through assessment of PAR2-mediated cellular responses. This segmentation allows systematic verification of each mechanism independently.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent employs multiple feedback mechanisms to validate 1-PPA's dual-mode action: transcriptional feedback through mRNA quantification and functional feedback through cellular response measurements. This comprehensive feedback system confirms that 1-PPA effectively inhibits PAR2 at both the transcriptional and functional levels.

Inventive Principle:

Principle #23Feedback

3Measurement precision

If 1-PPA interacts with PAR2 binding site, then functional inhibition is achieved, but molecular docking models must accurately predict the interaction site

Engineering Contradiction:

Improvebinding site accuracyVSAvoidcomputational modeling

Core Design Contradiction:

Measurement precisionVSDevice complexity

Solution Approach 1:

The patent uses molecular docking computational models to create virtual copies of the PAR2 receptor and 1-PPA molecule, allowing prediction of their interaction site without physical experimentation. The computational model accurately reproduces the binding geometry and interaction energy, enabling identification of the precise binding site before wet-lab validation.

Inventive Principle:

Principle #26Copying

Data Source

PatentUS20260014132A1Protease activated receptor 2 (PAR2) inhibitor and its uses

Publication Date: 2026.01.15 UNIV DEGLI STUDI DI PADOVA

AI summary

The present invention relates to a PAR2 inhibitor, in particular to 1-piperidine propionic acid or to pharmaceutical compositions comprising it, for use in the treatment or prevention or to assist the treatment or prevention of PAR2-related pathological conditions.